Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HENGRUI PHARMA's SHR-3079 Injection Approved for Clinical Trials
Recommend 4 Positive 5 Negative 1 |
||||
|
||||
|
HENGRUI PHARMA (01276.HK) announced that its subsidiary, Suzhou Suncadia Biopharmaceuticals, has received the Drug Clinical Trial Approval Notice for the SHR-3079 injection issued by the National Medical Products Administration, and will commence clinical trials in the near term. SHR-3079 injection is an innovative anti-tumor drug independently developed by the company, and is intended for the treatment of B-cell non-Hodgkin lymphoma. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
